

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

This Drug Coverage Decision supersedes the Drug Coverage Decision for the drug and indications dated January 29, 2019	
Drug	glecaprevir-pibrentasvir
Brand Name	Maviret™
Dosage Form(s)	100 mg/40 mg tablet
Manufacturer	AbbVie Corporation
Submission Type	New Submission
Use Reviewed	For the treatment of chronic hepatitis C (CHC)
Common Drug Review (CDR)	Yes, CDR recommended: to Reimburse with clinical criteria and/or conditions . Visit the CDR website for more details: https://www.cadth.ca/sites/default/files/cdr/complete/SR0523_Maviret_complete-Jan-25-18.pdf
Provincial Review	The DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the CDEC recommendation and an internal review only. The DBC screened Maviret™ on November 6, 2017. The DBC advised that because glecaprevir-pibrentasvir is similar to some of the other drugs used for the treatment of CHC, the Ministry may accept the CDEC recommendation for glecaprevir-pibrentasvir.
Drug Coverage Decision	Limited Coverage Benefit. Access the glecaprevir-pibrentasvir criteria from www.gov.bc.ca/pharmacarespecialauthority
Date	March 21, 2019 (This supersedes the listing decision for the drug and indications dated January 29, 2019)
Reason(s)	<p>Drug coverage decision is consistent with CDEC recommendation.</p> <ul style="list-style-type: none"> • Maviret™ reported high cure rates (based upon sustained viral response), is generally well-tolerated, and offers a shorter 8 weeks duration of therapy for treatment-naïve HCV patients without cirrhosis. • Based on economic considerations and the submitted product price, Maviret™ was not cost effective and/or did not offer optimal value for money. • The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer, which were able to address the concerns identified by CDEC with respect to cost-effectiveness and value for money. • Effective March 21, 2019, PharmaCare is expanding the Maviret™ criteria for the treatment of adult patients with CHC genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis, including adult patients with CHC genotype 1 infection who were previously treated with direct-acting antivirals (DAA).
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.